CD4

GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines

Retrieved on: 
Monday, January 9, 2023
COVID-19, CD8, Cancer, Algorithm, Therapy, RNA transfection, Epitope, Biotechnology, GRNA, Vaccine, Bladder cancer, Partnership, CD4, PBC, Serum Institute of India, Samsung Biologics, Patient, RNA, Research, Abraham Ancer, Shingles, NIH, Green-light

Under this collaboration, the companies will design and develop new personalized mRNA cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.

Key Points: 
  • Under this collaboration, the companies will design and develop new personalized mRNA cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.
  • EpiVax Therapeutics was the first personalized vaccine company to use computational tools to identify tolerogenic epitopes in neoantigens and to exclude these from cancer vaccine designs.
  • Together, GreenLight and EpiVax Therapeutics will leverage their respective expertise and jointly develop and commercialize potential novel personalized mRNA-based vaccine candidates for a wide range of oncology indications.
  • “We are delighted to partner with EpiVax Therapeutics, to expedite development of personalized cancer vaccine candidates using GreenLight’s RNA platform,” said Andrey Zarur, CEO of GreenLight.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress

Retrieved on: 
Thursday, December 8, 2022
RNA, Immunotherapy, Annual report, Security (finance), SD, Ovarian cancer, Marketing, LILRB2, Hypothyroidism, Induction, Nivolumab, RO, Society for Immunotherapy of Cancer, Interval (mathematics), Clinical trial, Tumor microenvironment, Inflammation, Macrophage, Safety, Congress, Cancer, PD-1, Large-cell lung carcinoma, Gilead Sciences, Trae tha Truth, CI, PFS, PD-L1, Ligand, CCR8, NSCLC, SELECT, RECIST, ORR, Immune system, Patient, ILT4, Bone pain, ICOS, Poster, Immunoglobulin G, Pharmacokinetics, Toxic epidermal necrolysis, CD4, IO, Cachexia, Appendix, Therapy, Partnership, Pharmaceutical industry, Vaccine, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported new clinical data from the INNATE trial with JTX-8064 and pimi and the SELECT trial with vopra and pimi in two poster presentations at the ESMO-IO 2022 Annual Congress being held in Geneva, Switzerland.

Key Points: 
  • Pimivalimab is currently being assessed in the INNATE Phase 1/2 trial (NCT04669899) in combination with JTX-8064, a LILRB2 (ILT4) inhibitor.
  • Pimivalimab is also being assessed in the SELECT Phase 2 clinical trial (NCT04549025) in combination with vopratelimab.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

Retrieved on: 
Thursday, December 15, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Immunotherapy, ASCT, Diffuse large B-cell lymphoma, Partial, Hematological Cancer Research Investment and Education Act, IMV, Rutgers Cancer Institute of New Jersey, CD8, Endpoint security, Survivin, Pembrolizumab, CD4, ORR, SEDAR, Cancer, RWJBarnabas Health, TSX, DPX, Immune system, Cyclophosphamide, Bladder cancer, Degenerative disease, Patient, EDGAR, PD-L1, Pharmaceutical industry, Medical imaging, DLBCL

He added: We find it remarkable that we have seen complete responses in this trial in patients that were refractory to prior cellular therapy and other advanced therapies.

Key Points: 
  • He added: We find it remarkable that we have seen complete responses in this trial in patients that were refractory to prior cellular therapy and other advanced therapies.
  • Clinical activity in a highly refractory patient population may represent a path to registration in DLBCL.
  • The VITALIZE Phase 2B trial is a randomized, parallel group, Simon two-stage study designed to assess IMVs lead candidate, MVP-S, in combination with pembrolizumab with or without cyclophosphamide.
  • A Phase 1 clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was initiated in early 2022.

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DLBCL, Toronto Stock Exchange, Immune system, EDGAR, Corporation, Immunotherapy, Survivin, CD8, IMV, Bladder cancer, CD4, TSX, SEDAR, DPX, Hematological Cancer Research Investment and Education Act, Vaccine

IMV Inc. (the Corporation or IMV) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today.

Key Points: 
  • IMV Inc. (the Corporation or IMV) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today.
  • The consolidation has taken effect on December 7, 2022, and the Corporations common shares commence trading on the Toronto Stock Exchange and on the Nasdaq Capital Market (Nasdaq) under the name IMV Inc. on a post-consolidation basis at the opening of markets today.
  • The consolidation is primarily intended to bring the Corporation into compliance with the minimum required closing bid price for continued listing on Nasdaq of US$1.00 per share.
  • IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Corporations immune-educating platform, DPX.

Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Oncology, Health, Infectious Diseases, Genetics, Other Health, Clinical Trials, Biotechnology, Genome, DLBCL, Infection, Dana–Farber Cancer Institute, Intellectual property, Leukemia, Society, NHL, Privacy, Follicular lymphoma, Research, Gene editing, Epidemiology, B-cell lymphoma, SEC filing, COVID-19, Growth, CAR, Neurotoxicity, Lymphatic system, CD19, Safety, DOI, CD4, Medical director, Pharmacokinetics, Insurance, Vaccine, Pharmaceutical industry, Security (finance), Patient

Autologous CAR T therapy remains one of the most promising approaches in the treatment of hematological malignancies.

Key Points: 
  • Autologous CAR T therapy remains one of the most promising approaches in the treatment of hematological malignancies.
  • Unlike autologous CAR T cell therapy, all allogeneic CAR T products are cryopreserved, which may alter the effective dose and composition of the post-thaw product.
  • The analysis found that CAR T expansion, a key determinant of durable response, strongly correlated with non-apoptotic CAR T cell dose.
  • These results indicate that the post-thaw CAR T product composition drives in vivo cell expansion potential and CAR T-related adverse events.

IMV Shareholders Approve Reverse Stock Split at 88%

Retrieved on: 
Wednesday, December 7, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, DLBCL, Immune system, EDGAR, Corporation, Immunotherapy, Letter, Survivin, Indian stock exchange, CD8, IMV, Bladder cancer, CD4, SEDAR, DPX, Security (finance)

As a result of the reverse stock split, every 10 Common Shares issued and outstanding will be automatically reclassified into one new Common Share.

Key Points: 
  • As a result of the reverse stock split, every 10 Common Shares issued and outstanding will be automatically reclassified into one new Common Share.
  • The reverse stock split will not modify any rights or preferences of the Common Shares.
  • The Common Shares issued pursuant to the reverse stock split will remain fully paid and non-assessable.
  • Computershare Investor Services Inc. (Computershare), IMVs transfer agent, is acting as the exchange agent for the reverse stock split.